ArticleOpen veterinary journal2025
The protective effects of garlic (
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A real-world data analysis of piroxicam in the FDA Adverse Event Reporting System (FAERS) database.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Piroxicam, a nonsteroidal antiinflammatory drug, is commonly used to induce inflammation in experimental models of inflammatory bowel disease (IBD). Piroxicam can modulate the immune system and disrupt the mucosal barrier, leading to increased production of reactive oxygen species. Aim: This study aimed to evaluate the effects of single-clove garlic ( Methods: The study used a completely randomized design with 30 male Wistar rats aged 2 months and weighing 150-200 g. The rats were divided into five groups: negative control (C), receiving CMC-Na 0,5% only; positive control (T0), receiving 20 mg/kgBW piroxicam; and three treatment groups, receiving 20 mg/kgBW piroxicam combined with 75 mg/kgBW (T1), 100 mg/kgBW (T2), or 125 mg/kgBW (T3) of SGE. Piroxicam was administered orally to induce inflammation, followed by SGE treatment for 14 days. Liver histopathological images were measured for damage repair using the scoring method. Superoxide dismutase and malondialdehyde levels were measured using enzyme-linked immunosorbent assay methods. Results: The results showed a significant increase in SOD levels ( Conclusion: SGE is a potent antioxidant that reduces oxidative stress in a piroxicam-induced IBD model and contributes to good health. Further studies are needed to explore the molecular mechanisms underlying these effects and to optimize the therapeutic potential of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.